Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q4 FY2018 Earnings Presentation
20 slides from Dr. Lal Pathlabs's earnings presentation, May 14, 2018
Slide 1: Dr. Lal PathLabs Limited (DLPL) Q4 & FY18 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q4 & FY18 Results Presentation May 14, 2018
Slide 2: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 3: Q4 FY18 Snapshot
Q4 FY18 Snapshot 21.4% Revenues INR 2,668 mn Samples Processed ~8.99 mn 26.3% EBITDA INR 688 mn Patients Tested ~3.85 mn 27.2% PAT INR 402 mn Total Employees ~4316 3
Slide 4: Kolkata Regional Reference Lab
Kolkata Regional Reference Lab Testing operations commenced in Jan 2018 – stabilization in progress Kolkata Reference Lab started testing of samples in early Jan. The World-class Lab will cater the demand from Northeast as well as Eastern regions of India. It will also cater to neighboring internati
Slide 5: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Performance Highlights 3 Financial Table 4 Financial Highlights 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Shareholding 10 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at
Slide 6: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs 193 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi and Regional Ref lab at diagnostic services Kolkata), 2,153 Patient Service Centers (PSCs) and 5624 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 1110 te
Slide 7: Key Performance Highlights
Key Performance Highlights Strong volume momentum achieved in Q4 expected to continue; captures growth in patient volumes and tests per patient. Initiatives of test bundling thereby delivering greater value to customers, and focus on specialised tests aiding growth momentum During Q4 FY18: • Recorde
Slide 8: Financial Table
Financial Table Particulars (Rs. mn) Q4 FY18 Q4 FY17 Growth % FY2018 FY2017 Growth % Total Revenue 2,668.4 2,199.2 21.4% 10,569.2 9,123.8 15.8% Total Expenditure 2028.2 1,700.4 7,929.2 6,748.7 EBITDA 640.2 498.8 28.3% 2,640.0 2374.6 11.2% Adj for RSU, and stock 48.1 46.1 142.7 104.9 based comp. & CS
Slide 9: Financial Highlights: Revenues
Financial Highlights Revenues All figures in Rs. mn 2,668 Q4 showed strong growth in Realisation per patient has 2,199 revenues at 21.4% to Rs. 2,668 improved marginally to Rs. 694 million. Drivers during the quarter owing to price rationalisations were: undertaken during the year in • Expansion
Slide 10: Financial Highlights: Normalised EBITDA
Financial Highlights All figures in Rs. mn Normalised EBITDA (after eliminating the impact of RSU and other stock based remuneration charges) 688 Q4 normalised operating EBITDA Q4 Normalised EBITDA margin 545 (after eliminating the impact of was at 25.8% vs 24.8% last RSU, other stock based year
Slide 11: Financial Highlights: PBT and PAT
Financial Highlights PBT All figures in Rs. mn 620 488 Q4 PBT stood at Rs. 620 million Q4 PAT stood at Rs. 402 million vs. Rs. 488 million in same quarter vs Rs. 316 million in Q4 last year previously Q4 FY17 Q4 FY18 2613 2368 12M PBT rose 10.3% to Rs. 2,613 12M PAT increased 10.4% to millio
Slide 12: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs 2153 No. of PUPs 1,759 189 193 1,559 164 172 1,340 5,668 5624 4,967 5,021 FY15 FY16 FY17 FY18 FY15 FY16 FY17 FY18 FY15 FY16 FY17 FY18 No. of patients (mn) No. of samples (mn) 34.7 15.2 29.3 13.3 26.3 12.0 9.9 21.7 9.0 19.0 FY14 FY15 FY16
Slide 13: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; “We have demonstrated a strong performance during the quarter with annual revenues crossing Rs 10 bn for the first time! This performance continues to be backed by our focus on providi
Slide 14: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services Initiatives to improve brand con
Slide 15: Corporate Overview
Corporate Overview • DLPL Strategy for future growth • Experienced Management team 15
Slide 16: DLPL Strategy for future growth
DLPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 16
Slide 17: DLPL Strategy for future growth
DLPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Lif
Slide 18: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Whole-time Director and Chief Chairman and Managing Director Whole-time Director Executive Officer Dilip Bidani Bharath Uppiliappan Shankha Banerjee Chief Financial Officer Chief Operating Officer Chief Growth
Slide 19: Shareholding as of 31st March, 2018
Shareholding as of 31st March, 2018 57.4% 10.1% 13.3% Promoter and Mutual FII Promoter Fund Group 0.2% 19.0% DII Others 19
Slide 20: Contact us
Contact us About Dr Lal PathLabs Limited (DLPL) For further information please contact: Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. Dilip Bidani It has an integrated nationwide network, where patients Dr. Lal PathLabs Limited and healthcare pro